Aerie pharmaceuticals, inc. completes enrollment in the phase 2 trial of ar-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion ahead of schedule

Aerie pharmaceuticals, inc. announced that patient enrollment in its phase 2 clinical trial of ar-1105 in patients with macular edema due to retinal vein occlusion (rvo) is complete several weeks ahead of schedule. ar-1105 is an investigational sustained-release, bio-erodible intravitreal implant containing dexamethasone. the phase 2 study (ar-1105-cs201), conducted at 19 centers in the united states, had an enrollment target of 45 patients. the trial is evaluating two formulations of ar-1105 (cf-1 and cf-2) that differ in the duration of dexamethasone release. a few additional patients are currently being screened and, if they are randomized, could bring the total number of patients in the final evaluation to a maximum of 49. the primary objectives of the trial are to evaluate the safety, tolerability and efficacy of the ar-1105 dexamethasone intravitreal implant. safety and efficacy will be evaluated at six months.
AERI Ratings Summary
AERI Quant Ranking